摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

azane;[(2R,3S,4R,5R)-5-[6-chloro-4-(methylamino)imidazo[4,5-c]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate | 1226907-52-3

中文名称
——
中文别名
——
英文名称
azane;[(2R,3S,4R,5R)-5-[6-chloro-4-(methylamino)imidazo[4,5-c]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
英文别名
——
azane;[(2R,3S,4R,5R)-5-[6-chloro-4-(methylamino)imidazo[4,5-c]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate化学式
CAS
1226907-52-3
化学式
C12H16ClN4O7P*H3N
mdl
——
分子量
411.739
InChiKey
IEGXSVDNTZSRHW-OVFHRJCNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.02
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    160
  • 氢给体数:
    6
  • 氢受体数:
    11

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Frontal Affinity Chromatography−Mass Spectrometry Useful for Characterization of New Ligands for GPR17 Receptor
    摘要:
    The application of frontal affinity chromatography mass spectrometry (FAC-MS), along with molecular modeling studies, to the screening of potential drug candidates toward the recently deorphanized G-protein-coupled receptor (GPCR) GPR17 is shown. GPR17 is dually activated by uracil nucleotides and cysteinyl-leukotrienes, and is expressed in organs typically undergoing ischemic damage (i.e., brain, heart and kidney), thus representing a new pharmacological target for acute and chronic neurodegeneration. GPR17 was entrapped on an immobilized artificial membrane (IAM), and this stationary phase was used to screen a library of nucleotide derivatives by FAC-MS to select high affinity ligands. The chromatographic results have been validated with a reference functional assay ([S-35]GTP gamma S binding assay). The receptor nucleotide-binding site was studied by setting up a column where a mutated GPR17 receptor (Arg255Ile) has been immobilized. The chromatographic behavior of the tested nucleotide derivatives together with in silico studies have been used to gain insights into the structure requirement of GPR17 ligands.
    DOI:
    10.1021/jm901691y
  • 作为产物:
    描述:
    1-(6-chloro-4-methylamino-imidazo[4,5-c]pyridin-1-yl)-β-D-1-deoxy-ribofuranose 在 磷酸三甲酯三氯氧磷三乙胺碳酸氢铵 作用下, 以 为溶剂, 反应 3.0h, 以88%的产率得到azane;[(2R,3S,4R,5R)-5-[6-chloro-4-(methylamino)imidazo[4,5-c]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
    参考文献:
    名称:
    Frontal Affinity Chromatography−Mass Spectrometry Useful for Characterization of New Ligands for GPR17 Receptor
    摘要:
    The application of frontal affinity chromatography mass spectrometry (FAC-MS), along with molecular modeling studies, to the screening of potential drug candidates toward the recently deorphanized G-protein-coupled receptor (GPCR) GPR17 is shown. GPR17 is dually activated by uracil nucleotides and cysteinyl-leukotrienes, and is expressed in organs typically undergoing ischemic damage (i.e., brain, heart and kidney), thus representing a new pharmacological target for acute and chronic neurodegeneration. GPR17 was entrapped on an immobilized artificial membrane (IAM), and this stationary phase was used to screen a library of nucleotide derivatives by FAC-MS to select high affinity ligands. The chromatographic results have been validated with a reference functional assay ([S-35]GTP gamma S binding assay). The receptor nucleotide-binding site was studied by setting up a column where a mutated GPR17 receptor (Arg255Ile) has been immobilized. The chromatographic behavior of the tested nucleotide derivatives together with in silico studies have been used to gain insights into the structure requirement of GPR17 ligands.
    DOI:
    10.1021/jm901691y
点击查看最新优质反应信息

文献信息

  • Frontal Affinity Chromatography−Mass Spectrometry Useful for Characterization of New Ligands for GPR17 Receptor
    作者:Enrica Calleri、Stefania Ceruti、Gloria Cristalli、Claudia Martini、Caterina Temporini、Chiara Parravicini、Rosaria Volpini、Simona Daniele、Gabriele Caccialanza、Davide Lecca、Catia Lambertucci、Maria Letizia Trincavelli、Gabriella Marucci、Irving W. Wainer、Graziella Ranghino、Piercarlo Fantucci、Maria P. Abbracchio、Gabriella Massolini
    DOI:10.1021/jm901691y
    日期:2010.5.13
    The application of frontal affinity chromatography mass spectrometry (FAC-MS), along with molecular modeling studies, to the screening of potential drug candidates toward the recently deorphanized G-protein-coupled receptor (GPCR) GPR17 is shown. GPR17 is dually activated by uracil nucleotides and cysteinyl-leukotrienes, and is expressed in organs typically undergoing ischemic damage (i.e., brain, heart and kidney), thus representing a new pharmacological target for acute and chronic neurodegeneration. GPR17 was entrapped on an immobilized artificial membrane (IAM), and this stationary phase was used to screen a library of nucleotide derivatives by FAC-MS to select high affinity ligands. The chromatographic results have been validated with a reference functional assay ([S-35]GTP gamma S binding assay). The receptor nucleotide-binding site was studied by setting up a column where a mutated GPR17 receptor (Arg255Ile) has been immobilized. The chromatographic behavior of the tested nucleotide derivatives together with in silico studies have been used to gain insights into the structure requirement of GPR17 ligands.
查看更多

同类化合物

4-氨基-1-(2’,3’,5’-三-O-叔-丁基二甲基硅烷基-beta-D-呋喃核糖基)-咪唑并[4,5-a]吡啶 3-脱氮腺苷 3-去氮杂鸟苷酸 3-去氮杂鸟苷三磷酸酯 3-去氮杂鸟苷 1-(2-脱氧-beta-D-赤式-呋喃戊糖基)-1H-咪唑并[4,5-c]吡啶-4-胺 1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-4,6-二氯咪唑并[4,5-c]吡啶 5'-O-(N-L-seryl)sulfamoyl-3-deaza-adenosine 5'-O-(N-glycyl)sulfamoyl-3-deaza-adenosine 5'-O-(N-L-isoleucyl)sulfamoyl-3-deaza-adenosine 2-Fluoro-3-deaza-adenosine 4-(pyridin-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine 4-cyclopropyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-methyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine Adenosine, 3-deaza- (2R,3S,5R)-5-(4-Dimethylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol (2R,3S,5R)-2-Hydroxymethyl-5-(4-mercapto-imidazo[4,5-c]pyridin-1-yl)-tetrahydro-furan-3-ol 4-chloro-7-fluoro-1-(2'-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 4-ethyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(Methylsulfanyl)-1-pentofuranosyl-1H-imidazo[4,5-c]pyridine 4,7-difluoro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 6-Chloro-n,n-dimethyl-1-pentofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine 2-(6-Chloro-4-methoxyimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(4-Benzylsulfanyl-6-chloroimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(6-Chloro-4-methylsulfanylimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-[4-bromo-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-6-yl]acetamide 5,6-Diamino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-4-one 1-amino-3-deazaguanosine 3-deazainosine 6-chloro-4-(cyclohexylamino)-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine [(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(4,6-dichloroimidazo[4,5-c]pyridin-1-yl)-4-methyloxolan-2-yl]methyl benzoate 4-amino-6-chloro-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine 4-amino-1-(2-deoxy-b-d-ribofuranosyl)-7-(1-naphthylethynyl)-imidazo[4,5-c]pyridine 3-Deazaguanosine 3',5'-cyclic phosphate 4-chloro-7-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(1H-pyrazol-5-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 2-bromo-5-methyl-1-(2,3,5-tri-O-t-butyldimethyl-silyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridin-4(5H)-one 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-chloro-1-(2',3'-dideoxy-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-β-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-(furan-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine